OSE Immunotherapeutics SA
PAR:OSE

Watchlist Manager
OSE Immunotherapeutics SA Logo
OSE Immunotherapeutics SA
PAR:OSE
Watchlist
Price: 6.53 EUR 2.83%
Market Cap: 143.3m EUR

P/E
Price to Earnings

3.1
Current
-4.2
Median
21.6
Industry
Higher than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
3.1
=
Market Cap
142.1m EUR
/
Net Income
46m EUR
Earnings Growth PEG
FR
OSE Immunotherapeutics SA
PAR:OSE
Average P/E: 73.4
3.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -172 668.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
89.3
88%
1
US
Amgen Inc
NASDAQ:AMGN
41.6
44%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
291.4
185%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -246.5 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -494.8 N/A N/A
AU
CSL Ltd
ASX:CSL
27.9
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.9
11%
1.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.3 N/A N/A
NL
argenx SE
XBRU:ARGX
43.9
19%
2.3

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
2.8
2-Years Forward
P/E
8.7
3-Years Forward
P/E
-10.7